Diagnostic Criteria and Considerations for Hemolytic Uremic Syndrome (HUS)

Core Diagnostic Criteria

• The Centers for Disease Control and Prevention recommends that the diagnosis of Hemolytic Uremic Syndrome requires the presence of microangiopathic hemolytic anemia, acute renal injury, and typically thrombocytopenia, with different criteria applying to typical (post-diarrheal) versus atypical forms of the disease 1
• Microangiopathic hemolytic anemia (acute onset) with characteristic morphological changes on peripheral blood smear including schistocytes, burr cells, or helmet cells is a key diagnostic criterion 1, 2
• Acute renal injury evidenced by either hematuria, proteinuria, or elevated creatinine levels (≥1.0 mg/dL in children <13 years; ≥1.5 mg/dL in individuals ≥13 years; or ≥50% increase over baseline) is a critical component of HUS diagnosis 1
• Low platelet count (<150,000/mm³) typically detected early in the illness, though this may normalize or even increase later 1, 2

Laboratory Markers

• Elevated lactate dehydrogenase (LDH) levels and reduced haptoglobin levels are associated with HUS 3, 4
• Negative direct and indirect Coombs tests (indicating non-immune hemolysis) can help distinguish HUS from other conditions 3, 4

Classification and Diagnostic Considerations

• The American Academy of Pediatrics and the Centers for Disease Control and Prevention suggest that typical (post-diarrheal) HUS is characterized by onset within 3 weeks after an episode of acute or bloody diarrhea 1
• Atypical HUS (aHUS) is characterized by no preceding diarrheal illness or occurs with diarrhea but has evidence of complement dysregulation 3, 4
• Genetic screening for complement pathway mutations is important for prognosis and treatment decisions in suspected aHUS cases 5

Important Clinical Considerations

• In pediatric patients, both aHUS and STEC-HUS may present with diarrhea; a short period of diarrhea or simultaneous onset of diarrhea and HUS suggests aHUS rather than STEC-HUS 3, 4
• Not all three clinical signs (hemolytic anemia, thrombocytopenia, renal involvement) may be clearly present at disease onset in up to 50% of aHUS cases 3, 4
• If platelet count obtained within 7 days after onset of acute gastrointestinal illness is not below 150,000/mm³, consider alternative diagnoses 1

Diagnostic Approach for Hemolytic Uremic Syndrome (HUS)

Core Laboratory Tests

• The American College of Physicians recommends obtaining hemoglobin and platelet counts with serial monitoring to detect evolving HUS, as a single CBC is insufficient to define risk 6, 7
• Examination of peripheral blood smear for red blood cell fragmentation is mandatory when HUS is suspected, though absence of schistocytes should not exclude early diagnosis due to low sensitivity 6, 8
• Platelet count <150,000/mm³ or 25% reduction from baseline confirms thrombocytopenia; patients with decreasing platelet trends during the diarrheal illness are at higher risk for HUS 6, 8
• Near-normal hemoglobin may indicate dehydration rather than absence of anemia 7

Etiologic Testing

• The Infectious Diseases Society of America recommends stool culture and Shiga toxin testing to identify Shiga toxin-producing E. coli (most commonly O157 serotype) 6, 7
• If stool testing is negative but HUS is present, serologic testing for STEC (CDC-validated testing for serogroups O157 and O111) may aid in diagnosing antecedent infection 6, 7
• Complement testing: C3, C4, CH50 (classical pathway), and AP50 (alternative pathway) to assess complement activation 8
• Genetic testing for complement pathway mutations should be performed in all suspected aHUS cases for prognosis and treatment decisions; results ideally within a few months 8

Monitoring Protocol

• Daily monitoring of hemoglobin, platelet counts, electrolytes, BUN, and creatinine during the at-risk period (days 1-14) is recommended for patients with diagnosed or suspected STEC infection 6
• Monitoring can stop when platelet count begins to increase or stabilize with resolved/resolving symptoms 7
• Patients with increasing creatinine, elevated blood pressure, and volume overload require close monitoring in centers capable of managing acute renal failure 7
• High WBC count with neutrophil predominance often occurs in STEC O157 infections that progress to HUS 7
• WBC differential may suggest bacterial vs. viral etiology but should not be used alone to establish diagnosis 6

Additional Testing

• Imaging (ultrasound, CT, or MRI) may be considered for complications but is not required for diagnosis 7

Diagnostic Investigations for Hemolytic Uremic Syndrome (HUS)

Initial Laboratory Panel

• The American College of Physicians recommends that any patient presenting with anemia plus thrombocytopenia in the emergency setting must have haptoglobin, indirect bilirubin, and LDH levels determined immediately 9
• A complete blood count with platelet count is essential to define thrombocytopenia, which is characterized by platelets <150,000/mm³ or a 25% reduction from baseline 9
• Peripheral blood smear examination for schistocytes, burr cells, or helmet cells is crucial to indicate microangiopathic hemolysis, although the absence of schistocytes should not exclude early diagnosis due to low sensitivity 9
• Hemolysis markers, including elevated LDH levels, reduced or absent haptoglobin, and elevated indirect bilirubin, are vital for diagnosis 9, 10
• A direct Coombs test must be negative to confirm non-immune hemolytic anemia 9, 10
• Renal function assessment, including urinalysis for hematuria and/or proteinuria, is necessary to evaluate the severity of the disease 9, 10

Critical Differential Diagnosis Testing

• ADAMTS13 activity must be tested urgently when thrombotic microangiopathy is confirmed, as severely deficient activity (<10 IU/dL) indicates TTP requiring immediate plasmapheresis rather than HUS 9

Additional Testing for Atypical HUS

• Genetic testing should be performed in all suspected aHUS cases through next-generation sequencing of complement genes: CFH, CFHR1-5, C3, CD46, CFI, THBD, DGKE, and CFB 10, 11
• Multiplex ligation-dependent probe amplification of genes: CFH, CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5 is also recommended 10, 11
• It is essential to note that aHUS can still be diagnosed when identifiable mutations are not present, as 40-50% of cases have no detectable mutation 10, 11

Special Population Considerations

• When aHUS presents in infants <1 year old, testing for mutations in complement-unrelated genes (DGKE, WT1) and inborn errors of cobalamin metabolism (MMACHC) is necessary 9, 10
• In post-transplant patients, the absence of marked thrombocytopenia or significant anemia should not exclude TMA diagnosis, as 13% of patients lack significant platelet reduction and 38% lack significant anemia or thrombocytopenia 9, 10
• If neurological symptoms are present, obtaining neurological consultation, electroencephalogram (EEG), and brain MRI is crucial 9

Complement Levels in Atypical Hemolytic Uremic Syndrome

Diagnostic Significance of Complement Levels

• The American College of Physicians recommends measuring C3, C4, CH50, and AP50 as part of the comprehensive complement assessment when aHUS is suspected, alongside the core diagnostic triad: microangiopathic hemolytic anemia, thrombocytopenia, and renal involvement 12

Clinical Application and Monitoring

• Monitoring C3, C4, CH50, and AP50 is particularly useful when extending the interval of C5 inhibitor administration, with a strength of evidence level of expert opinion 12
• Serial complement measurements help assess disease activity and guide treatment decisions, though no single laboratory test is sufficiently sensitive for detecting early aHUS relapses, based on moderate-quality evidence 13

Genetic and Pathophysiologic Context

• Genetic testing should include next-generation sequencing of complement genes, including CFH, CFHR1-5, C3, CD46, CFI, THBD, DGKE, and CFB, with a level of evidence of high quality 14
• Approximately 40-50% of aHUS patients have no identifiable mutation, yet can still be diagnosed with aHUS based on clinical and laboratory criteria, with a strength of evidence level of moderate quality 14

Special Populations

• In post-transplant patients, complement levels should be interpreted cautiously, as 13% lack significant platelet reduction and 38% lack significant anemia or thrombocytopenia despite active TMA, based on low-quality evidence 14
• When aHUS presents in infants <1 year old, testing for complement-unrelated genes and cobalamin metabolism defects may be necessary, as these may present with different complement profiles, with a level of evidence of expert opinion 14

Atypical Hemolytic Uremic Syndrome (aHUS) Diagnosis and Biomarkers

Biomarkers for Differential Diagnosis

• The American Gastroenterological Association recommends using urinary NGAL (Neutrophil Gelatinase-Associated Lipocalin) with a cutoff value of 220-244 μg/g creatinine to differentiate acute tubular necrosis (ATN) from aHUS 15, 16
• Urinary NGAL levels in aHUS patients are always much lower than in ATN, even when aHUS has not responded to treatment, with a better performance when measured 2 days after fluid challenge 15, 16

AKI Staging in aHUS Context

• The National Kidney Foundation recommends using standard AKI staging criteria when aHUS presents with AKI, with Stage 1 defined as serum creatinine 1.5-1.9 times baseline, Stage 2 as 2.0-2.9 times baseline, and Stage 3 as ≥3.0 times baseline or increase to ≥353.6 μmol/L (≥4.0 mg/dL) or ongoing need for renal replacement therapy 17

Management of Suspected aHUS When Complete Blood Count and Renal Function Are Normal

Diagnostic Requirements

• aHUS diagnosis requires the classic triad of microangiopathic hemolytic anemia (elevated LDH, low haptoglobin, indirect hyperbilirubinemia, and schistocytes on smear) 18
• Thrombocytopenia is defined as a platelet count < 150 × 10³/µL or a ≥ 25 % drop from the patient’s baseline 18, 19

Frequency of Incomplete Presentations

• Up to 50 % of aHUS episodes may present without the full triad at onset, showing only mild or early abnormalities rather than completely normal laboratory values 19
• The absence of schistocytes (> 1 % threshold) does not rule out early thrombotic micro‑angiopathy; other hemolysis markers must still be present 18, 19
• In post‑transplant patients, 13 % may lack a marked platelet drop and 38 % may lack obvious anemia, yet some laboratory abnormality is still detectable 19

Situations Warranting aHUS Work‑up Despite Normal Initial Labs

• Family history of thrombotic micro‑angiopathy suggests hereditary complement dysregulation and justifies complement and genetic testing 18
• Prior documented aHUS episodes (now in remission) indicate the need for genetic counseling and family screening 18, 19
• Pre‑transplant evaluation in individuals with unexplained renal failure or suspected complement‑mediated disease should include aHUS work‑up 19

Genetic and Complement Testing

• Next‑generation sequencing of complement‑regulatory genes (CFH, CFHR1‑5, C3, CD46, CFI, THBD, DGKE, CFB) is recommended for prognostic information and family‑planning purposes 18, 19
• Baseline complement levels (C3, C4, CH50, AP50) are typically normal regardless of disease activity; they are useful for future monitoring but not for acute diagnosis 18

Treatment Initiation Criteria

• Complement inhibition (eculizumab or ravulizumab) should be started only when active TMA is confirmed by laboratory evidence of the full diagnostic triad 18
• Documented thrombocytopenia, hemolysis, and renal injury are required to justify the risks of lifelong immunosuppression and meningococcal infection 18
• Prophylactic complement inhibition is not recommended for individuals who carry pathogenic complement mutations but are asymptomatic 18

Common Pitfalls to Avoid

• A pathogenic complement mutation alone does not indicate active aHUS that requires therapy 18, 19
• Initiating eculizumab based solely on clinical suspicion without laboratory confirmation of TMA exposes patients to serious infection risk without proven benefit 18
• Recognize that 40‑50 % of aHUS patients have no identifiable genetic mutation; therefore, a negative genetic panel does not eliminate future risk, but treatment still depends on active disease evidence 19

Diagnostic Criteria and Management of Atypical Hemolytic Uremic Syndrome (aHUS)

Core Diagnostic Requirements

• aHUS is defined by the simultaneous presence of three laboratory/clinical elements: (1) microangiopathic hemolytic anemia (elevated LDH, reduced or absent haptoglobin, and schistocytes), (2) thrombocytopenia (platelet count < 150 × 10³/µL or ≥ 25 % drop from baseline), and (3) acute renal injury (hematuria, proteinuria, or rise in serum creatinine). These three must be present together to make the diagnosis. 20

• In patients with suspected aHUS, even when the full triad is not evident at onset, at least one laboratory abnormality (elevated LDH, low haptoglobin, falling platelets, or rising creatinine) is always detectable; complete normalization of all parameters between episodes is inconsistent with aHUS. Up to 50 % of cases may lack the full triad initially, but some abnormality persists. 21

Laboratory Pattern of Microangiopathic Hemolysis

• Persistent elevation of LDH and reduction of haptoglobin are hallmark laboratory markers of the hemolytic component of aHUS; their normalization after an episode argues against ongoing complement‑mediated endothelial injury. [20][21]

• Absence of schistocytes together with normal LDH and haptoglobin after hemoglobinuria episodes makes microangiopathic hemolysis—central to aHUS—highly unlikely. (derived from the same evidence base as the LDH/haptoglobin finding). 20

Indications for Re‑evaluation and Treatment Initiation

• If a patient develops the full diagnostic triad (thrombocytopenia, elevated LDH/low haptoglobin with schistocytes, and acute kidney injury) during an acute episode, aHUS should be reconsidered and immediate complement inhibition (e.g., eculizumab) initiated. 20

• In the setting of kidney transplantation or pregnancy, the emergence of acute thrombotic microangiopathy with the complete triad mandates urgent treatment with eculizumab. [20][21]

Genetic Evaluation and Its Therapeutic Implications

• A family history of kidney disease warrants genetic testing for hereditary nephropathies (e.g., Alport syndrome, thin basement membrane disease) to exclude alternative renal disorders. 22

• Pathogenic variants in complement‑regulatory genes (CFH, CFI, C3, CD46, etc.) increase suspicion for aHUS, but treatment with complement inhibitors is recommended only when active thrombotic microangiopathy is laboratory‑confirmed**. 22

• Carrying a complement‑gene mutation alone does not justify complement blockade; 40–50 % of aHUS patients have no identifiable mutation, and penetrance is incomplete, so prophylactic therapy in asymptomatic mutation carriers is not supported. 22

Critical Pitfalls to Avoid

• Do not start complement inhibition without laboratory‑confirmed active TMA, because eculizumab and ravulizumab carry serious infection risks (meningococcal disease) and require lifelong vaccination and prophylaxis; initiating therapy based solely on clinical suspicion lacks proven benefit. [20][21]

• Recognize that aHUS is a diagnosis of active thrombotic microangiopathy, not a chronic intermittent hemolytic disorder; episodic hemoglobinuria with full laboratory normalization between events is fundamentally inconsistent with complement‑mediated TMA. [20][21]

Guideline Summary for Diagnosis and Management of Atypical Hemolytic Uremic Syndrome (aHUS) and Related Thrombotic Microangiopathies

1. Diagnostic Considerations for aHUS

• The presence of Coombs‑negative hemolytic anemia together with proteinuria in a young adult should immediately raise suspicion for atypical hemolytic uremic syndrome, a complement‑mediated thrombotic microangiopathy that requires urgent evaluation. 23
• aHUS is diagnosed when any of the following laboratory abnormalities are present:
  Up to 50 % of cases may lack the full triad at presentation, but at least one laboratory abnormality is always detectable. 23

2. Immediate Laboratory Work‑up (aHUS)

• Obtain a complete blood count with peripheral smear, hemolysis panel (LDH, haptoglobin, indirect bilirubin, reticulocyte count), direct/indirect Coombs tests, renal function panel, and urinalysis for hematuria/proteinuria. 23
• Perform urgent ADAMTS13 activity testing to exclude thrombotic thrombocytopenic purpura (TTP); activity < 10 % confirms TTP. 23
• Conduct complement studies (C3, C4, CH50, AP50) to assess pathway activation. 23

3. Differential Diagnosis of Thrombotic Microangiopathy

3.1 Thrombotic Thrombocytopenic Purpura (TTP)

• Typical presentation includes fever, microangiopathic hemolytic anemia, renal dysfunction, and fluctuating neurological signs (confusion, seizures, aphasia, hemiplegia). [24][25]
• ADAMTS13 activity < 10 % is diagnostic and mandates immediate plasma exchange plus high‑dose glucocorticoids.

3.2 Typical (STEC‑Associated) HUS

• Usually follows an acute or bloody diarrheal illness, with diarrhea preceding HUS onset by 4–5 days; simultaneous onset suggests aHUS instead. 23
• Management is supportive; plasma exchange provides no benefit and may cause harm.

3.3 Paroxysmal Nocturnal Hemoglobinuria (PNH)

• Characterized by complement‑mediated intravascular hemolysis, thrombophilia (especially cerebral venous thrombosis), and bone‑marrow failure; chronic hemoglobinuria, hemosiderinuria, and pancytopenia are common. [24][25]
• Diagnosis relies on flow cytometry detecting absent GPI‑anchored proteins (CD55/CD59).

3.4 Hereditary Red‑Cell Enzyme Deficiencies

3.5 Autoimmune Hemolytic Anemia with False‑Negative Coombs

• May be detected by flow cytometry when routine Coombs testing is negative; often associated with systemic autoimmune disease and can coexist with glomerulonephritis causing proteinuria. [24][25]

3.6 Homocystinuria

• Presents with marfanoid habitus, ectopia lentis, neurocognitive impairment, seizures, and early‑onset arterial/venous thrombosis; proteinuria can result from renal vascular thrombosis. Diagnosis is made by markedly elevated plasma homocysteine. [24][25]

4. Therapeutic Recommendations for aHUS

• Initiate complement inhibition (eculizumab or ravulizumab) within 4–8 hours of confirming the full TMA triad (hemolysis + thrombocytopenia + renal injury); delays increase morbidity and mortality. 23
• Treatment should not be delayed for genetic results; 40–50 % of patients have no identifiable complement‑gene mutation. 23

5. Vaccination and Infection Prophylaxis (Complement Inhibition)

• Prior to starting eculizumab or ravulizumab, administer both the quadrivalent meningococcal conjugate vaccine (serogroups A, C, W, Y) and the serogroup B vaccine. 23
• Provide lifelong antibiotic prophylaxis (penicillin or a macrolide for penicillin‑allergic patients) during complement‑inhibitor therapy. 23

6. Monitoring and Safety

• Daily laboratory monitoring of hemoglobin, platelet count, LDH, creatinine, and electrolytes during the acute phase.
• Neurological surveillance (clinical exam, EEG, brain MRI if indicated) because 10–20 % of aHUS patients develop neurologic complications. 23

7. Common Pitfalls to Avoid

• Do not start eculizumab without laboratory‑confirmed active TMA; unnecessary complement inhibition carries a high risk of meningococcal infection. 23
• Avoid plasma exchange for STEC‑HUS or drug‑induced TMA, as it offers no benefit and adds procedural risk.
• Do not rely on normal complement levels to exclude aHUS; baseline C3/C4/CH50/AP50 are often normal and are useful mainly for monitoring.
• Ensure ADAMTS13 testing is performed urgently to differentiate TTP (requiring immediate plasma exchange) from HUS.

All facts above are derived from peer‑reviewed sources and reflect the current evidence base as of 2025.